KR20250153311A - 재조합 단백질 생산 방법 - Google Patents

재조합 단백질 생산 방법

Info

Publication number
KR20250153311A
KR20250153311A KR1020257033442A KR20257033442A KR20250153311A KR 20250153311 A KR20250153311 A KR 20250153311A KR 1020257033442 A KR1020257033442 A KR 1020257033442A KR 20257033442 A KR20257033442 A KR 20257033442A KR 20250153311 A KR20250153311 A KR 20250153311A
Authority
KR
South Korea
Prior art keywords
cells
batch
cell
culture
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257033442A
Other languages
English (en)
Korean (ko)
Inventor
지안린 수
앤드류 용키
준 티안
마이클 씨. 보리스
젱지안 리
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250153311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20250153311A publication Critical patent/KR20250153311A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020257033442A 2018-07-03 2019-07-02 재조합 단백질 생산 방법 Pending KR20250153311A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862693606P 2018-07-03 2018-07-03
US62/693,606 2018-07-03
PCT/US2019/040298 WO2020010080A1 (en) 2018-07-03 2019-07-02 Methods of producing recombinant proteins
KR1020217003056A KR102870511B1 (ko) 2018-07-03 2019-07-02 재조합 단백질 생산 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003056A Division KR102870511B1 (ko) 2018-07-03 2019-07-02 재조합 단백질 생산 방법

Publications (1)

Publication Number Publication Date
KR20250153311A true KR20250153311A (ko) 2025-10-24

Family

ID=67470657

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257033442A Pending KR20250153311A (ko) 2018-07-03 2019-07-02 재조합 단백질 생산 방법
KR1020217003056A Active KR102870511B1 (ko) 2018-07-03 2019-07-02 재조합 단백질 생산 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217003056A Active KR102870511B1 (ko) 2018-07-03 2019-07-02 재조합 단백질 생산 방법

Country Status (23)

Country Link
US (2) US20210253996A1 (https=)
EP (2) EP3818078B1 (https=)
JP (3) JP7419273B2 (https=)
KR (2) KR20250153311A (https=)
CN (1) CN112839954A (https=)
AU (1) AU2019299358B2 (https=)
CA (1) CA3104684A1 (https=)
DK (1) DK3818078T3 (https=)
EA (1) EA202092904A1 (https=)
ES (1) ES2976708T3 (https=)
FI (1) FI3818078T3 (https=)
HR (1) HRP20240584T1 (https=)
HU (1) HUE066560T2 (https=)
IL (2) IL324666A (https=)
LT (1) LT3818078T (https=)
MX (1) MX2020013633A (https=)
PL (1) PL3818078T3 (https=)
PT (1) PT3818078T (https=)
RS (1) RS65472B1 (https=)
SG (1) SG11202012582QA (https=)
SI (1) SI3818078T1 (https=)
SM (1) SMT202400173T1 (https=)
WO (1) WO2020010080A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK181991B1 (en) * 2021-11-11 2025-05-15 Dsm Ip Assets Bv Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s)) in escherichia coli
WO2023242238A1 (en) * 2022-06-15 2023-12-21 UCB Biopharma SRL Cell culture processes
EP4339274B1 (en) 2022-09-13 2025-03-26 Sartorius Stedim Biotech GmbH Method for operating a bioprocess installation for production of a bioproduct
KR20240172522A (ko) * 2023-06-01 2024-12-10 (주)알테오젠 지속형 호르몬 수용체 길항제의 생산 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941344B1 (en) 1996-11-27 2004-05-19 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
PT2837680T (pt) * 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
WO2015095809A1 (en) * 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
MA40021A (fr) * 2014-06-03 2015-12-10 Lupin Ltd Processus de culture cellulaire destiné à produire une protéine
AU2015269365A1 (en) * 2014-06-04 2016-12-15 Amgen Inc. Methods for harvesting mammalian cell cultures
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
US20210253996A1 (en) 2021-08-19
AU2019299358B2 (en) 2026-04-02
IL324666A (en) 2026-01-01
CA3104684A1 (en) 2020-01-09
IL279782A (en) 2021-03-01
CN112839954A (zh) 2021-05-25
WO2020010080A1 (en) 2020-01-09
PL3818078T3 (pl) 2024-04-29
EP4368699A2 (en) 2024-05-15
BR112020025623A2 (pt) 2021-03-23
IL279782B1 (en) 2026-01-01
SMT202400173T1 (it) 2024-07-09
JP2024050590A (ja) 2024-04-10
PT3818078T (pt) 2024-04-18
JP7419273B2 (ja) 2024-01-22
ES2976708T3 (es) 2024-08-07
EP3818078A1 (en) 2021-05-12
AU2019299358A1 (en) 2021-02-18
EP3818078B1 (en) 2024-02-28
FI3818078T3 (fi) 2024-05-14
DK3818078T3 (da) 2024-05-21
MX2020013633A (es) 2021-03-25
US20250171732A1 (en) 2025-05-29
JP2021529527A (ja) 2021-11-04
EP4368699A3 (en) 2024-09-11
SI3818078T1 (sl) 2024-05-31
KR20210027427A (ko) 2021-03-10
HRP20240584T1 (hr) 2024-07-19
KR102870511B1 (ko) 2025-10-15
SG11202012582QA (en) 2021-01-28
LT3818078T (lt) 2024-04-25
RS65472B1 (sr) 2024-05-31
JP2026048825A (ja) 2026-03-17
HUE066560T2 (hu) 2024-08-28
EA202092904A1 (ru) 2021-04-22

Similar Documents

Publication Publication Date Title
US20250171732A1 (en) Methods of producing recombinant proteins
JP2023075125A (ja) 細胞バンクの解凍復元を改善するためのｐＨ調整
KR20220039777A (ko) 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
US11242510B2 (en) Mammalian cells devoid of lactate dehydrogenase activity
US20090142805A1 (en) High expression cell line that eliminates gene amplification
US12486525B2 (en) Methods for increasing productivity of therapeutic proteins
EA048403B1 (ru) Способы получения рекомбинантных белков
BR112020025623B1 (pt) Método para a produção, em grande escala, de um polipeptídeo recombinante de interesse
US20250115666A1 (en) Cell culture methods for producing therapeutic proteins
HK40002355A (en) Methods of decreasing trisulfide bonds during recombinant production of polypeptides

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000